Munjal focus on CDMO-R&D services
BSE-listed Remedium Lifecare of Mumbai is prioritizing global expansion, especially entering new international geographies and strengthening its presence in existing markets.
It is also executing a long-term growth plan aimed at expanding its research and development (R&D) focus across key therapeutic areas such as anti-infectives, cardiovascular, and central nervous system (CNS) treatments.
This initiative will strengthen its innovation pipeline and ensure the development of advanced healthcare solutions, said Adarsh Munjal, Managing Director of Remedium Lifecare https://fieo.org/.
“Our focus is to build a robust foundation for Contract Development and Manufacturing Organisation (CDMO) and R&D services that will position Remedium to secure new contracts, drive innovation, and improve margins through backward integration. Enhancing working capital will further improve inventory and supply chain management, ensuring seamless operations across its distribution network.
“These strategic initiatives, combined with its robust Q1 performance, will enable Remedium Lifecare to enhance operational resilience, drive innovation, and consolidate its leadership in both domestic and international markets,” he said on 11 Aug https://www.bseindia.com/.
Remedium reported a Profit After Tax (PAT) of Rs.464.88 lakhs for quarter ended 30 June 2025, a significant improvement from the loss of Rs.204.60 lakhs recorded in the previous quarter ended 31 March 2025.
A rapidly growing player in the pharmaceutical supply chain and specialty chemicals sector, the company said Q1 PAT has already surpassed the company’s total PAT for the entire FY25, which stood at Rs.212.94 lakhs, highlighting strong operational momentum and a sharp rebound in profitability.
Munjal said, “This quarter marks a significant milestone for Remedium Lifecare. Our focused strategy on operational efficiency and prudent financial management has resulted in a robust turnaround, with Q1 PAT surpassing the entire FY25 profit https://www.nseindia.com/.
“We remain committed to building on this momentum and delivering sustained value to our shareholders while driving growth in our core healthcare and pharmaceutical segments.” Founded in 1988, Remedium Lifecare Ltd. is a BSE-listed pharmaceutical company engaged in the trading and distribution of raw material as a supply chain management for the pharmaceutical industry with an emphasis on quality, compliance, and global reach, the company continues to expand its presence while playing a pivotal role in India’s pharmaceutical ecosystem. Fiinews.com
